| Budget Amount *help |
¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aimed to develop the highly personalized cancer immunotherapy targeting neoantigen. We found that BALB/c mouse-derived one colorectal cell line and two fibrosarcoma cell lines possessed 200~300 nonsynonymous mutations. Utilizing these cell lines, we demonstrated that anti-tumor effect of neoantigen-targeted adoptive T cell therapy was enhanced by the vaccination targeting macrophages in tumor. Moreover, we demonstrated the the adoptive T cell therapy targeting neoantigen was enhanced by a novel substance X that activated NF-kB pathway in neoantigen-specific T cells.
|
